Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

May 5, 2017May 5, 2017

Asbestos-disease Groups Blast 7 Producer Countries’ Bid to Keep Profits Rolling in

News

Seven countries that mine asbestos have prevented a form of it known as chrysotile asbestos from being added to the United Nations Rotterdam Convention‘s list of substances that are so hazardous that ... Read more

April 10, 2017April 10, 2017

Verastem Presents Its Mesotheliomia Therapy Defactinib at New York Conference

News

Verastem‘s mesothelioma therapy Defactinib (VS-6063), which a 2016 report said shrank tumors in almost a third of patients in a Phase 2 clinical trial, was featured at the recent 16th Annual Needham Healthcare Conference ... Read more

February 6, 2017

ADAO Announces Agenda for 13th Annual Asbestos Conference

News

An award-winning investigative journalist, a Montana lawmaker and a popular musician will headline the 13th Annual Asbestos Prevention and Awareness Conference, set for April 7-9 in the Washington, D.C., area. ... Read more

January 6, 2017February 23, 2017

SELLAS to Present Corporate and Clinical Updates at Upcoming Conference

News

SELLAS Life Sciences will present corporate and clinical updates on its novel cancer immunotherapies at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, Jan 9-13. According to a press release, Angelos Stergiou, ... Read more

November 15, 2016

Aduro Presents Positive Early Data from Phase 1b Mesothelioma Trial Evaluating Combo Treatment

News

Combining the cancer vaccine CRS-207 with standard of care chemotherapy and cyclophosphamide looks like a promising first-line treatment for patients with unresectable malignant pleural mesothelioma, according to preliminary data from the second cohort of ... Read more

November 8, 2016

Epizyme Updates Clinical Trial Data on Tazemotostat for Mesothelioma, Other Cancers

News

Epizyme has reported recent updates from its clinical-stage programs with the company’s lead candidate, tazemotostat, for the treatment of hematological malignancies and genetically defined solid tumors. Tazemotostat, a first-in-class small molecule, oral ... Read more

November 4, 2016

McCulloch Appointed to Pacific Mesothelioma Center Board of Directors

News

Alexa McCulloch has been appointed treasurer on the board of directors of the Pacific Mesothelioma Center (PMC), a division of the Pacific Heart, Lung & Blood Institute (PHLBI). McCulloch has held numerous ... Read more

November 2, 2016November 2, 2016

Targovax Reports Promising Early Data on Vaccine Now in Mesothelioma Clinical Trial

News

Targovax recently presented preclinical and clinical results of the anti-tumor efficacy of its cancer vaccine ONCOS-102 for the treatment of malignant mesothelioma. The presentation, “OR52: Anti-tumor potency of cancer vaccine ... Read more

October 21, 2016October 21, 2016

Sellas Life Sciences Names Jonathan Eckard as New Chief Business and Strategy Officer

News

Sellas Life Sciences recently named Jonathan Eckard, PhD, as its chief business and strategy officer. Eckard’s doctorate in toxicology and carcinogenesis is from NYU School of Medicine, where he also earned a master’s ... Read more

September 16, 2016September 16, 2016

SELLAS Collaborates with NIH to Develop Gene-Monitoring Assay for Cancer Immunotherapies

News

SELLAS Life Sciences has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. National Heart, Lung and Blood Institute of the National Institutes of Health (NIH). CRADA ... Read more